Leveraging transcriptomic data to pinpoint mechanisms of gemcitabine resistance and potential combination therapies for pancreatic cancer.

e15730Background: Pancreatic cancer has an estimated 5-year survival rate of only 5-6% and is often diagnosed after metastasis has occurred. Gemcitabine or gemcitabine combination therapies are fre...